Today’s 13GD Alert: Therapeuticsmd, Inc: Wellington Management Group Llp Opened Big New Position

Today's 13GD Alert: Therapeuticsmd, Inc: Wellington Management Group Llp Opened Big New Position

The New Wellington Management Group Llp Holding in Therapeuticsmd, Inc

Wellington Management Group Llp filed with the SEC SC 13G/A form for Therapeuticsmd, Inc. The form can be accessed here: 000090221916001231. As reported in Wellington Management Group Llp’s form, the filler as of late owns 6.93% or 13,608,413 shares of the Health Care–company.

Therapeuticsmd, Inc stake is a new one for the for this institutional investor and it was filed because of activity on September 30, 2016. We feel this shows Wellington Management Group Llp’s positive view for the stock. For a institutional investor managing $826.00 billion in assets and having 1540+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

Therapeuticsmd, Inc Institutional Sentiment

Latest Security and Exchange filings show 109 investors own Therapeuticsmd, Inc. The institutional ownership in Q3 2015 is high, at 59.62% of the outstanding shares. This is increased by 8053015 the total institutional shares. 117148884 were the shares owned by these institutional investors. In total 14 funds opened new Therapeuticsmd, Inc stakes, 48 increased stakes. There were 17 that closed positions and 34 reduced them.

Stoneridge Investment Partners Llc is an institutional investor bullish on Therapeuticsmd, Inc, owning 509872 shares as of Q3 2015 for 0.42% of its portfolio. Sphera Funds Management Ltd owns 512500 shares or 0.38% of its portfolio. NY Morgens Waterfall Vintiadis & Co Inc have 0.58% of their stock portfolio for 180000 shares. Further, Gilder Gagnon Howe & Co Llc reported stake worth 0.48% of its US stock portfolio. The MA Ra Capital Management Llc owns 1518460 shares. Therapeuticsmd, Inc is 1.28% of the manager’s US portfolio.

Business Profile

TherapeuticsMD, Inc. is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. The Company manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins. The Company’s product line includes vitaTrue, vitaPearl, vitaMedMD Plus, vitaMedMD One Prenatal Multivitamin, vitaMedMD Plus Rx Prenatal Multivitamin, vitaMedMD One Rx Prenatal Multivitamin, vitaMedMD RediChew Rx Prenatal Multivitamin, vitaMedMD Iron 21/7, itaMedMD Menopause Relief with Lifenol Plus Bone Support, vitaMedMD Vitamin D3 50,000 IU, BocaGreenMD Prena1 Pearl and BocaGreenMD Prena1 Chew.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Wellington Management Group Llp website.

Insitutional Activity: The institutional sentiment decreased to 1.25 in Q2 2016. Its down 0.78, from 2.03 in 2016Q1. The ratio dived, as 19 funds sold all TherapeuticsMD Inc shares owned while 29 reduced positions. 13 funds bought stakes while 47 increased positions. They now own 158.58 million shares or 4.25% more from 152.12 million shares in 2016Q1.

Granite Point Cap Mgmt L P, a Massachusetts-based fund reported 194,925 shares. Massachusetts Financial Ma has 0.01% invested in the company for 1.77 million shares. Proshare Advsr Ltd Company has 18,356 shares for 0% of their US portfolio. Moreover, Heartland Advsr has 0.29% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 600,000 shares. Atwood & Palmer has invested 0.01% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Legal & General Gru Public Ltd reported 41,455 shares or 0% of all its holdings. The Illinois-based Guggenheim Cap Ltd has invested 0% in TherapeuticsMD Inc (NYSEMKT:TXMD). Deutsche National Bank Ag has 0% invested in the company for 161,339 shares. American Century Companies Inc has 159,821 shares for 0% of their US portfolio. Teachers Advisors has 237,923 shares for 0% of their US portfolio. Kistler has 1,000 shares for 0% of their US portfolio. Nationwide Fund Advisors owns 133,478 shares or 0% of their US portfolio. Blackrock Gp Limited, a United Kingdom-based fund reported 99,375 shares. Employees Retirement Association Of Colorado holds 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD) for 40,500 shares. Millennium Mgmt Ltd has 0.01% invested in the company for 372,275 shares.

Analysts await TherapeuticsMD Inc (NYSEMKT:TXMD) to report earnings on November, 2. They expect $-0.11 EPS, 0.00% or $0.00 from last year’s $-0.11 per share. After $-0.11 actual EPS reported by TherapeuticsMD Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

About 82,250 shares traded hands. TherapeuticsMD Inc (NYSEMKT:TXMD) has risen 6.48% since March 8, 2016 and is uptrending. It has underperformed by 2.84% the S&P500.

TherapeuticsMD, Inc. is a women’s healthcare product company. The company has a market cap of $1.39 billion. The Company’s segment is creating and commercializing products for women. It currently has negative earnings. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products.

TherapeuticsMD Inc (NYSEMKT:TXMD) Ratings Coverage

Out of 3 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $33 is the highest target while $14.0 is the lowest. The $21.67 average target is 218.68% above today’s ($6.8) stock price. TherapeuticsMD has been the topic of 4 analyst reports since September 21, 2015 according to StockzIntelligence Inc. The rating was maintained by Jefferies with “Buy” on Monday, September 21. The stock has “Buy” rating given by Stifel Nicolaus on Tuesday, December 8. The firm earned “Buy” rating on Tuesday, December 8 by Jefferies.

Another recent and important TherapeuticsMD Inc (NYSEMKT:TXMD) news was published by Fool.com which published an article titled: “Here’s Why TherapeuticsMD Inc. Fell 11.5% in August” on September 12, 2016.

According to Zacks Investment Research, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.”

TXMD Company Profile

TherapeuticsMD, Inc., incorporated on July 20, 2010, is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. The Firm is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The Company’s drug candidates used in its clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. The Company’s drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. The Firm makes and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment